UT Austin Research Commercialization Hits Record High in 2025 Report
- 159 inventions disclosed in 2025, a university record.
- Over 100 licenses and options executed, including 49 to Texas startups.
- 19 startups launched, raising $68 million in venture funding.
- Licensing revenue hit $2.9 million, up from $2 million in 2024.
- Two FDA-approved therapies and a cancer diagnostic kit reached the market.
The University of Texas at Austin's research commercialization arm, Discovery to Impact, has released its 2025 annual report. The report marks a breakout year for turning university research into real-world products and companies. Key metrics all surged, with invention disclosures, licenses, startups, and revenue hitting new highs.
Invention Disclosures Hit Record 159
Researchers filed 159 invention disclosures in 2025, the highest number in university history. This represents a 23% increase over the previous year. The rise spans multiple fields, from engineering and computing to life sciences.
UT Austin now holds over 1,200 active patents. The university's technology portfolio includes advances in semiconductors, artificial intelligence, and biomedical devices.
Licensing Activity Surges Past 100 Deals
Discovery to Impact executed more than 100 licenses and options during the year. Of those, 49 went to Texas-based startups, reinforcing the university's role in the state's innovation economy. The licensing team streamlined processes, reducing average deal times by 30%.
One notable deal involved a novel battery technology licensed to an Austin-based clean energy firm. Terms were not disclosed, but the startup has already secured pilot manufacturing funding.
Startups Raise $68 Million, Two Therapies Reach Market
Nineteen startups spun out from UT Austin research in 2025. They collectively raised $68 million in venture capital and grants. The companies focus on drug discovery, quantum computing, and water purification.
Two FDA-approved therapies developed from UT research reached patients this year. A diagnostic kit for early-stage ovarian cancer also entered clinical use. Licensing revenue from these and other products reached $2.9 million, up from $2 million in 2024.
Industry Partnerships Expand
Corporate research agreements grew 40% year-over-year. Major partners included Samsung, Apple, and Merck. These partnerships fund specific projects and give companies first access to new inventions.
The university also launched a new 'Innovation Fellows' program. It places graduate students inside startup incubators to accelerate technology transfer.
Discovery to Impact director Dr. Carol F. said the results show 'a culture shift' among faculty. 'Researchers are thinking about translation earlier in their work,' she noted. 'That's driving our numbers.'
Looking ahead, Discovery to Impact plans to expand its venture fund and hire more licensing officers. The goal is to maintain this momentum through 2026 and beyond.